UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 273

Sortiert nach

Neuroblastoma

Pediatric blood & cancer, 2021-05, Vol.68 (S2), p.e28473-n/a

2021

Volltextzugriff (PDF)

Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

Cancer, 2022-11, Vol.128 (21), p.3775-3783

2022

Volltextzugriff (PDF)

Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma

Clinical cancer research, 2018-02, Vol.24 (4), p.939-949

2018

Volltextzugriff (PDF)

Afro‐descendant ethnicity does not negatively influence neuroblastoma survival in the French West Indies

Pediatric blood & cancer, 2024-08, Vol.71 (8), p.e31037-n/a

2024

Volltextzugriff (PDF)

Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma

Pediatric blood & cancer, 2018-04, Vol.65 (4), p.n/a

2018

Volltextzugriff (PDF)

Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas

Pediatric blood & cancer, 2014-06, Vol.61 (6), p.1101-1103

2014

Volltextzugriff (PDF)

A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high‐risk neuroblastoma: An International Neuroblastoma Risk Group project

Pediatric blood & cancer, 2021-03, Vol.68 (3), p.e28794-n/a

2021

Volltextzugriff (PDF)

Predictive factors of long-term follow-up attendance in very long-term childhood cancer survivors

Cancer, 2023-11, Vol.129 (21), p.3476-3489

2023

Volltextzugriff (PDF)

Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study

Pediatric blood & cancer, 2018-11, Vol.65 (11), p.e27363-n/a

2018

Volltextzugriff (PDF)

The challenge of defining “ultra‐high‐risk” neuroblastoma

Pediatric blood & cancer, 2019-04, Vol.66 (4), p.e27556-n/a

2019

Volltextzugriff (PDF)

Parental smoking, maternal alcohol consumption during pregnancy and the risk of neuroblastoma in children. A pooled analysis of the ESCALE and ESTELLE French studies

International journal of cancer, 2019-12, Vol.145 (11), p.2907-2916

2019

Volltextzugriff (PDF)

A subset of image‐defined risk factors predict completeness of resection in children with high‐risk neuroblastoma: An international multicenter study

Pediatric blood & cancer, 2024-10, Vol.71 (10), p.e31218-n/a

2024

Volltextzugriff (PDF)

Image‐defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy‐induced variation, and impact on surgical outcomes

Pediatric blood & cancer, 2017-11, Vol.64 (11), p.n/a

2017

Volltextzugriff (PDF)

Advances in Risk Classification and Treatment Strategies for Neuroblastoma

Journal of clinical oncology, 2015-09, Vol.33 (27), p.3008-3017

2015

Volltextzugriff (PDF)

Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection

Pediatric blood & cancer, 2015-09, Vol.62 (9), p.1543-1549

2015

Volltextzugriff (PDF)

Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma

International journal of cancer, 2019-11, Vol.145 (10), p.2781-2791

2019

Volltextzugriff (PDF)

Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue

Bone marrow transplantation (Basingstoke), 2021-08, Vol.56 (8), p.1984-1997

2021

Volltextzugriff (PDF)

Multidisciplinary surgical strategy for dumbbell neuroblastoma: A single‐center experience of 32 cases

Pediatric blood & cancer, 2019-08, Vol.66 (S3), p.e27670-n/a

2019

Volltextzugriff (PDF)

Outcome of children with relapsed or refractory neuroblastoma: A meta‐analysis of ITCC/SIOPEN European phase II clinical trials

Pediatric blood & cancer, 2017-01, Vol.64 (1), p.25-31

2017

Volltextzugriff (PDF)

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting

Journal of clinical oncology, 2017-08, Vol.35 (22), p.2580-2587

2017

Volltextzugriff (PDF)

Phase II study of 131 I-metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP

Pediatric blood & cancer, 2023-11, Vol.70 (11), p.e30615-e30615

2023

Volltextzugriff (PDF)

The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients

Journal of neuro-oncology, 2022-04, Vol.157 (2), p.355-364

2022

Volltextzugriff (PDF)

Tandem high-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuro-ectodermic tumors

Pediatric blood & cancer, 2014-08, Vol.61 (8), p.1398-1402

2014

Volltextzugriff (PDF)

1 – 25 von 273

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(254)
Mit Volltextzugriff
(246)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(170)
Life Sciences & Biomedicine
(165)
Humans
(163)
Oncology
(129)
Child
(112)
Female
(111)
Male
(108)
Child, Preschool
(104)
Infant
(101)
Adolescent
(82)
Neuroblastoma
(60)
Biological And Medical Sciences
(59)
Medical Sciences
(59)
Pediatrics
(58)
Prognosis
(49)
Tumors
(46)
Life Sciences
(42)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(38)
Hematology
(38)
Chemotherapy
(35)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Neuroblastoma

Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma

Afro‐descendant ethnicity does not negatively influence neuroblastoma survival in the French West Indies

Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial

Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma

Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas

A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high‐risk neuroblastoma: An International Neuroblastoma Risk Group project

Predictive factors of long-term follow-up attendance in very long-term childhood cancer survivors

Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study

Ovarian tissue cryopreservation for fertility preservation in 418 girls and adolescents up to 15 years of age facing highly gonadotoxic treatment. Twenty years of experience at a single center

The challenge of defining “ultra‐high‐risk” neuroblastoma

Parental smoking, maternal alcohol consumption during pregnancy and the risk of neuroblastoma in children. A pooled analysis of the ESCALE and ESTELLE French studies

A subset of image‐defined risk factors predict completeness of resection in children with high‐risk neuroblastoma: An international multicenter study

Image‐defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy‐induced variation, and impact on surgical outcomes

Advances in Risk Classification and Treatment Strategies for Neuroblastoma

Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection

Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma

Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue

Multidisciplinary surgical strategy for dumbbell neuroblastoma: A single‐center experience of 32 cases

Outcome of children with relapsed or refractory neuroblastoma: A meta‐analysis of ITCC/SIOPEN European phase II clinical trials

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting

Phase II study of 131 I-metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP

The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients

Tandem high-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuro-ectodermic tumors

Suchergebnisse filtern